Morgan Stanley Has Lowered Expectations for Zentalis Pharmaceuticals (NASDAQ:ZNTL) Stock Price

Zentalis Pharmaceuticals (NASDAQ:ZNTL) had its price target decreased by equities research analysts at Morgan Stanley from $8.00 to $4.00 in a research report issued on Wednesday,Benzinga reports. The brokerage presently has an “equal weight” rating on the stock. Morgan Stanley’s price objective indicates a potential upside of 199.63% from the stock’s current price.

Other analysts also recently issued research reports about the company. Weiss Ratings restated a “sell (e+)” rating on shares of Zentalis Pharmaceuticals in a research note on Wednesday, October 8th. Wedbush reaffirmed a “neutral” rating and set a $4.00 price target on shares of Zentalis Pharmaceuticals in a research report on Tuesday. Wells Fargo & Company decreased their target price on Zentalis Pharmaceuticals from $6.00 to $5.00 and set an “equal weight” rating on the stock in a research report on Thursday, August 7th. Wall Street Zen downgraded Zentalis Pharmaceuticals from a “hold” rating to a “sell” rating in a research report on Saturday. Finally, Leerink Partners restated a “market perform” rating and issued a $2.00 target price on shares of Zentalis Pharmaceuticals in a report on Tuesday. One investment analyst has rated the stock with a Strong Buy rating, one has issued a Buy rating, five have assigned a Hold rating and one has given a Sell rating to the company. Based on data from MarketBeat.com, the company has a consensus rating of “Hold” and a consensus price target of $5.03.

Zentalis Pharmaceuticals Trading Down 4.6%

Shares of NASDAQ ZNTL traded down $0.07 on Wednesday, reaching $1.34. 272,606 shares of the company traded hands, compared to its average volume of 1,096,820. The stock has a market capitalization of $96.31 million, a PE ratio of -0.64 and a beta of 1.87. Zentalis Pharmaceuticals has a fifty-two week low of $1.01 and a fifty-two week high of $4.44. The company has a 50 day moving average of $1.54 and a 200 day moving average of $1.45.

Zentalis Pharmaceuticals (NASDAQ:ZNTL) last posted its quarterly earnings results on Monday, November 10th. The company reported ($0.37) earnings per share for the quarter, topping analysts’ consensus estimates of ($0.49) by $0.12. As a group, research analysts expect that Zentalis Pharmaceuticals will post -2.42 earnings per share for the current year.

Institutional Trading of Zentalis Pharmaceuticals

A number of large investors have recently bought and sold shares of ZNTL. Catalyst Funds Management Pty Ltd acquired a new stake in Zentalis Pharmaceuticals in the 2nd quarter valued at about $31,000. Cerity Partners LLC boosted its position in Zentalis Pharmaceuticals by 58.7% during the 1st quarter. Cerity Partners LLC now owns 20,501 shares of the company’s stock valued at $33,000 after purchasing an additional 7,579 shares during the period. Qube Research & Technologies Ltd acquired a new stake in shares of Zentalis Pharmaceuticals in the 2nd quarter worth approximately $37,000. Y Intercept Hong Kong Ltd bought a new position in Zentalis Pharmaceuticals during the 2nd quarter valued at $38,000. Finally, Corient Private Wealth LLC bought a new stake in Zentalis Pharmaceuticals in the second quarter worth about $41,000.

Zentalis Pharmaceuticals Company Profile

Zentalis Pharmaceuticals, Inc, a clinical-stage biopharmaceutical company, focuses on discovering and developing small molecule therapeutics for the treatment of various cancers. Its products candidatures include the ZN-c3, an inhibitor of WEE1, a protein tyrosine kinase for the treatment of inhibitor for advanced solid tumors and hematological malignancies; in Phase 2 clinical trial as a monotherapy for the treatment of uterine serous carcinoma indications; Phase 2 clinical trial in Cyclin E1 driven high-grade serous ovarian cancer, fallopian tube, or primary peritoneal cancer; Phase 1/2 clinical trial in combination with PARPi for platinum-resistant ovarian cancer; Phase 1b clinical trial in combination with chemotherapy in platinum-resistant ovarian, and peritoneal or fallopian tube cancer; Phase 1/2 clinical trial in combination with chemotherapy in relapsed or refractory osteosarcoma; Phase 1/2 clinical trial with encorafenib and cetuximab for mutant metastatic colorectal cancer; and Phase 1/2 clinical trial in combination with chemotherapy in pancreatic cancer.